Journal of Clinical Oncology
Articles in this Issue
Fecal microbiota transplantation (FMT) combined with first-line gemcitabine and nab-paclitaxel chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC).
758 Background: Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer related deaths in Canada. There...
Coupling tumor genomics, whole transcriptome sequencing, and patient outcomes to define the tumor microenvironment in receptor tyrosine amplified gastrointestinal cancers: Analysis from 24,598 cases.
427 Background: The tumor microenvironment (TME) is increasingly appreciated as a modulator of response to standard chemot...
Multi-omics characterization of response to tyrosine kinase inhibitor plus immunotherapy in MSS/pMMR metastatic colorectal cancer: A multicenter biomarker study.
206 Background: Patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC), representing the v...
Race and income-related disparities in survival outcomes in patients with pancreatic neuroendocrine tumors: A SEER-based analysis.
672 Background: Racial and income-related disparities in gastrointestinal (GI) cancers influence access to care and surviv...
Clinical utility of the Idylla CDx MSI test in identifying MSI-H mCRC patients eligible for nivolumab monotherapy or in combination with ipilimumab therapy (CheckMate 8HW phase III trial).
28 Background: CheckMate 8HW (CA209-8HW), a Phase 3, randomized, 3-arm open-label study, evaluated nivolumab monotherapy (...
Efficacy and safety of trastuzumab deruxtecan in HER2-positive advanced gastric and gastroesophageal junction cancers: A meta-analysis of real-world studies and clinical trials.
402 Background: Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate (ADC) with a cytotoxic payload....
Efficacy and toxicity outcomes of total neoadjuvant FLOT versus perioperative FLOT in resectable gastric cancer: Results from the Turkish Oncology Gastrointestinal Cancer Working Group.
414 Background: In resectable gastric cancer, most patients are unable to complete the perioperative FLOT regimen (Per-FLO...
Colonoscopy choices in a changing world: Do gender preferences still exist for colonoscopy?
99 Background: Colorectal cancer screening (CRCs) is an important standard of care in modern medicine. Previous studies pe...
Gastrointestinal malignancies in Syria: An epidemiological analysis from the country’s main cancer center.
813 Background: Epidemiological data on gastrointestinal (GI) cancers in conflict-affected regions such as Syria are sever...
Survival benefit and toxicity of combining immunotherapy with gemcitabine-cisplatin versus standard chemotherapy in advanced cholangiocarcinoma: A meta-analysis.
572 Background: Cholangiocarcinoma (CCA) is a rare, and aggressive malignancy with limited treatment options, where gemcit...
Mode of presentation and symptoms of colorectal cancer (CRC) by primary tumor and molecular subgroup: A large-scale AI-powered analysis.
203 Background: The mode of presentation of CRC has implications for early detection and prognosis. Our aim was to charact...
Investigating the efficacy and use of immunotherapy in treatment of microsatellite instability low (MSI-L) solid tumors.
845 Background: The development of immune checkpoint inhibitors has changed the treatment approach for microsatellite inst...
GLP-1 receptor agonist use and pancreatic cancer risk in patients with chronic pancreatitis.
733 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have advanced the treatment of type 2 diabetes mellit...
Managing the primary tumor in patients with rectal cancer and synchronous liver metastases: The role of organ preservation.
155 Background: Modern therapy can achieve a clinical complete response (cCR) of the primary tumor in the patients with re...
REPERTOIRE: Real-world treatment (tx) patterns and outcomes in US patients (pts) with HER2-negative (HER2-) advanced gastric, gastroesophageal junction and esophageal adenocarcinoma (GC/GEJC/EAC).
306 Background: GC/GEJC/EAC is often diagnosed at an advanced stage, where there are limited tx options, particularly upon...
Effect of intraperitoneal CF33-hNIS combined with PD-L1 blockade on gastric cancer peritoneal metastases and recurrence.
433 Background: Peritoneal metastasis (PM) from gastric cancer (GC) carries a dismal prognosis and remains refractory to s...
A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).
TPS614 Background: Despite recent breakthroughs in first-line treatment of advanced HCC using immune checkpoint inhibitors...
Prognostic factors for rapid progression in metastatic pancreatic adenocarcinoma: Clinical, histopathological, and laboratory analysis.
681 Background: Metastatic pancreatic adenocarcinoma (mPAC) remains highly lethal despite modern chemotherapy. Outcome het...
Donafenib and sintilimab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A phase II, biomarker exploratory study (DosinTACE).
549 Background: Despite the combination of anti-angiogenics and immune checkpoint inhibitors being the standard for unrese...
A phase 2 study of STING agonist ADU-S100 combined with a CLDN18.2 bispecific antibody in patients with advanced pancreatic cancer.
749 Background: STING agonists can remodel the tumor immune microenvironment by inducing innate immunity and promoting ste...
Improving biomarker testing in patients with metastatic colorectal cancer through patient education.
100 Background: Biomarker testing in patients with metastatic colorectal cancer (mCRC) is essential for optimal and guidel...
Hepatocellular carcinoma in Nevada: Impact of HBV/HCV, metabolic syndrome, and alcohol use disorder on age at diagnosis and survival.
523 Background: Hepatocellular carcinoma (HCC) arises from diverse etiologies, most commonly chronic hepatitis B or C infe...
Role of cell-intrinsic C5AR1 in colorectal cancer survival and chemoresistance.
225 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Althoug...
A phase 2, open-label single-arm, multi-center study of trans-arterial tirapazamine embolization (TATE) combined with nivolumab (nivo) in patients with advanced immunotherapy-refractory hepatocellular carcinoma (HCC).
538 Background: Advanced HCC after failure of first line immunotherapy has limited options and is an urgent unmet need. Tr...
Real-world comparative outcomes of FOLFOX vs FOLFIRI as second-line therapy in metastatic biliary tract cancer.
582 Background: Biliary tract cancers (BTCs), including intrahepatic (IH) and extrahepatic (EH) cholangiocarcinoma and gal...